Cytori Therapeutics (NASDAQ:CYTX) during 2009, achieved the following:

* Grew system and consumable sales, predominantly into the cosmetic surgery market;
* Increased number of systems in the field that will further support consumable cartridge sales growth;
* Reported interim results from a post-marketing breast reconstruction study intended to support cosmetic and reconstructive surgery sales efforts in Europe and Asia;
* Expanded autologous fat graft product line with development of the PureGraft System (which received FDA clearance early 2010);
* Completed enrollment in two cardiovascular disease safety and feasibility trials with results to be reported in May 2010.